LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced the broadening of its NAD+ precursor intellectual property portfolio with the newly granted U.S. Patent number 10,000,520 C1 covering the composition of matter for the disodium salt of NMNH (dihydronicotinamide mononucleotide).

洛杉矶——（商业新闻短讯）——全球烟酰胺腺嘌呤二核苷酸（NAD+）研究权威机构ChromaDex Corp.（纳斯达克：CDXC）今天宣布，将扩大其NAD+前体知识产权组合，新授予的美国专利号为10000520 C1，涵盖NMNH（二氢烟酰胺单核苷酸）二钠盐的物质组成。

Co-owned with Queen's University Belfast (QUB), this patent solidifies ChromaDex’s leadership in the NAD+ precursor space..

该专利与贝尔法斯特女王大学（QUB）共同拥有，巩固了ChromaDex在NAD+前体领域的领先地位。。

ChromaDex continuously evaluates and investigates next-generation NAD+ precursors at the forefront of the burgeoning healthy aging category. The company owns and licenses a robust and secure portfolio of over 80 patents relating to its flagship patented nicotinamide riboside (NR) ingredient, Niagen®, and other NAD+ precursors including nicotinamide riboside triacetate (NRT), reduced nicotinamide riboside (NRH), nicotinic acid riboside (NAR), and now the newly granted NMNH patent..

ChromaDex不断评估和研究处于新兴健康老龄化领域前沿的下一代NAD+前体。该公司拥有并授权了一个强大而安全的专利组合，涉及其旗舰专利烟酰胺核苷（NR）成分，Niagen®和其他NAD+前体，包括烟酰胺核苷三乙酸酯（NRT），还原烟酰胺核苷（NRH），烟酸核苷（NAR），以及现在新授予的NMNH专利。。

Rob Fried, CEO of ChromaDex and Founder of Tru Niagen said, 'ChromaDex continues to lead the NAD+ field commercially and scientifically, with the broadest patent portfolio of NAD+ precursors. As this industry continues to expand, we are committed to innovation and maintaining the highest production quality standards.'.

ChromaDex首席执行官兼Tru Niagen创始人罗伯·弗里德（RobFried）表示，“ChromaDex继续在商业和科学上领导NAD+领域，拥有最广泛的NAD+前体专利组合。随着这个行业的不断扩大，我们致力于创新并保持最高的生产质量标准。”。

Not to be confused with NMN, which was banned as a dietary supplement by the U.S. FDA in 2022, NMNH is chemically distinct from NMN and a compound that has recently entered the U.S. market as an NAD+ precursor. While preclinical studies have demonstrated that NMNH can boost NAD+ levels when injected, further research is needed to determine if it is orally bioavailable and safe as a dietary supplement.

不要与NMN混淆，NMN在2022年被美国FDA禁止作为膳食补充剂，NMNH在化学上与NMN不同，NMN是一种最近作为NAD+前体进入美国市场的化合物。虽然临床前研究表明，注射NMNH可以提高NAD+水平，但需要进一步研究以确定其作为膳食补充剂是否具有口服生物利用度和安全性。

Furthermore, NMNH is a new dietary ingredient (NDI) which has not been properly notified to FDA, rendering its legal status as a dietary supplement questionable at present..

此外，NMNH是一种新的膳食成分（NDI），尚未正确告知FDA，目前其作为膳食补充剂的法律地位值得怀疑。。

One of the most robust forms of intellectual property protection, a composition of matter patent, grants ChromaDex exclusive rights to the disodium salt form of NMNH. Any company that develops a product using the disodium salt form of NMNH would infringe on ChromaDex’s patent.

最有力的知识产权保护形式之一是物质组成专利，它授予ChromaDex对NMNH二钠盐形式的专有权。任何使用NMNH二钠盐形式开发产品的公司都将侵犯ChromaDex的专利。

In addition to the disodium salt of NMNH, ChromaDex has also obtained protection for numerous other NMNH derivatives, including metallic salts such as lithium, potassium, and magnesium. Further, the patent adds protection for salt forms of NMNH. This broadens ChromaDex’s protection and opens new avenues for future product development and commercialization..

除了NMNH的二钠盐外，ChromaDex还获得了许多其他NMNH衍生物的保护，包括锂，钾和镁等金属盐。此外，该专利增加了对NMNH盐形式的保护。这拓宽了ChromaDex的保护范围，为未来的产品开发和商业化开辟了新途径。。

Granted by a three-examiner panel, this patent demonstrates the diligence of ChromaDex’s innovative research and development efforts.

该专利由三名审查员小组授予，证明了ChromaDex的创新研发努力。

For additional information on ChromaDex, visit www.chromadex.com.

有关ChromaDex的更多信息，请访问www.ChromaDex.com。

Forward-Looking Statements:

前瞻性声明：

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to commercial possibilities for NMNH, prospective enforcement of patent rights, and ongoing research and development efforts.

本版本包含经修订的《1933年证券法》第27A节和经修订的《1934年证券交易法》第21E节所指的前瞻性声明，包括与NMNH商业可能性、专利权的预期执行以及正在进行的研究和开发工作有关的声明。

Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as 'expects,' 'anticipates,' 'intends,' 'estimates,' 'plans,' 'potential,' 'possible,' 'probable,' 'believes,' 'seeks,' 'may,' 'will,' 'should,' 'could' or the negative of such terms or other similar expressions.

不描述历史事实的陈述构成前瞻性陈述，通常（但不总是）可以通过使用诸如“期望”、“预期”、“打算”、“估计”、“计划”、“潜在”、“可能”、“可能”、“相信”、“寻求”、“可能”、“意志”、“应该”、“可能”或这些术语或其他类似表达的否定词来识别。

Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition.

导致这些前瞻性声明不确定性的风险包括新型冠状病毒对我们的业务和全球经济的影响；我们的经营亏损历史以及需要获得额外融资；我们产品销售的增长和盈利能力；我们保持销售、营销和分销能力的能力；改变消费者对我们产品的看法；我们依赖单一或有限数量的第三方供应商；。

More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov.

有关ChromaDex和可能影响前瞻性陈述实现的风险因素的更多详细信息，请参阅ChromaDex截至2023年12月31日的10-K表年度报告、ChromaDex的10-Q表季度报告以及ChromaDex提交给SEC的其他文件，其副本可从SEC网站www.SEC.gov获得。

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of th.

提醒读者不要过度依赖这些前瞻性声明，因为这些声明仅在th时发表。

About ChromaDex:

关于ChromaDex：

ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+.

ChromaDex Corp.（纳斯达克：CDXC）是烟酰胺腺嘌呤二核苷酸（NAD+）的全球权威，专注于健康衰老科学。ChromaDex团队由世界著名科学家组成，与来自全球知名大学和研究机构的独立研究人员合作，以揭示NAD+的全部潜力。

A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality..

NAD+是人体每个细胞中发现的一种重要辅酶，随着年龄的增长和暴露于其他日常压力源而下降。NAD+耗竭是与年龄相关的健康和活力变化的原因。。

Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available.

ChromaDex将其作为科学严谨性、安全性、质量和透明度的黄金标准，是其经临床验证的旗舰成分Niagen（获得专利的烟酰胺核苷或NR）的创新者，Niagen是最有效和最优质的NAD+助推器。

Niagen is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States†. Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at www.truniagen.com)..

Niagen是ChromaDex消费品中的活性成分，以Tru Niagen®品牌出售，Tru Niagen®是美国排名第一的健康衰老NAD+补充剂†。临床证明，Tru Niagen可以提高NAD+水平，正在帮助世界各地的人们改变他们的衰老方式（可从www.truniagen.com获得）。。

ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, to which ChromaDex regularly publishes copies of its press releases, news, and financial information.

ChromaDex强大的专利组合保护NR和其他NAD+前体。ChromaDex在www.ChromaDex.com上维护一个网站，ChromaDex定期向其发布新闻稿、新闻和财务信息的副本。

†Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).

†根据美国最大电子商务市场（截至2023年3月1日至2024年2月29日）收入最高的膳食补充剂品牌。